Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.37 |
| ▸ | JAK2 | O60674 | 9/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | TYK2 | P29597 | 2/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | HCK | P08631 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2356780 | 0.87 | TDO2 (0.44) | MAPTTP53PANK3CHEK1JAK2 | |
| SCHEMBL15389627 | 0.83 | CHEK1 (0.44) | MAPTTP53CHEK1JAK2NPC1 | |
| SCHEMBL2356538 | 0.83 | CHEK1 (0.42) | MAPTTP53PANK3CHEK1JAK2 | |
| SCHEMBL2355684 | 0.83 | MAPT (0.44) | MAPTTP53PANK3CHEK1JAK2 | |
| SCHEMBL2302385 | 0.82 | TP53 (0.46) | MAPTTP53CHEK1JAK2NPC1 | |
| SCHEMBL2357981 | 0.82 | CHEK1 (0.43) | MAPTTP53CHEK1JAK2JAK3 | |
| SCHEMBL2358281 | 0.81 | JAK2 (0.43) | MAPTTP53CHEK1JAK2NPC1 | |
| SCHEMBL2359298 | 0.80 | TP53 (0.46) | MAPTTP53CHEK1JAK2JAK3 | |
| SCHEMBL2355740 | 0.80 | MAPT (0.46) | MAPTTP53CHEK1JAK2NPC1 | |
| SCHEMBL2355563 | 0.80 | MAPT (0.42) | MAPTTP53CHEK1JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | claimed |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | INCYTE CORPORATION | 2006-05-18 | — | — | US | claimed |
| WO-2005105814-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2005-11-10 | — | — | WO | claimed |
| US-20200093825-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION | 2020-03-26 | — | — | US | disclosed |
| US-20170087158-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2017-03-30 | — | — | US | disclosed |
| EP-3042655-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | Incyte Holdings Corporation (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| EP-2349260-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | Incyte Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION | 2010-05-06 | — | — | US | disclosed |
| WO-2010039939-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | INCYTE CORPORATION | 2009-08-27 | — | — | US | disclosed |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | INCYTE CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087158-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | MAPT 1843/4885TP53 3210/4885PANK3 177/4885 |
| US-20090215766-A1 | TETRACYCLIC INHIBITORS OF JANUS KINASES | JAK1, JAK2, JAK3 | MAPT 2554/4885TP53 1050/4885PANK3 207/4885 |
| US-20130310340-A1 | METHOD OF TREATING MUSCULAR DEGRADATION | PYGM, CKMT1A; CKMT1B, SMN1; SMN2 | MAPT 2214/4885TP53 3779/4885PANK3 2739/4885 |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | MAPT 2464/4885TP53 3995/4885PANK3 271/4885 |
| US-20200093825-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | MAPT 2464/4885TP53 3995/4885PANK3 271/4885 |
| US-20060106020-A1 | Tetracyclic inhibitors of Janus kinases | JAK1, JAK2, JAK3 | MAPT 2554/4885TP53 1050/4885PANK3 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.